Humana Inc.

(New York Stock Exchange)
Back to all articles
Very Bullish +85

What Humana (HUM) Said on Its Q3 Earnings Call - Yahoo Finance

Earnings report Guidance raised Joint venture AI-generated analysis

πŸ“ˆ Humana raised its full-year 2026 adjusted earnings forecast to at least $9.50 per share from $9 due to favorable Medicare Part D performance and controlled medical costs.

πŸ‘₯ Early Medicare Advantage enrollment trends are ahead of expectations, with the company anticipating membership growth in 2027.

πŸ’° Humana expects material margin improvement next year, targeting an individual Medicare Advantage margin above 3% in 2028.

⭐ Medicare Stars ratings exceeded the top-quartile goal with a member-weighted rating of 4.17, potentially providing a one-time financial tailwind in 2028.

🀝 A new joint venture with BlackRock reduces the company's cost of capital and lowers its GAAP debt-to-capital ratio by approximately 130 basis points.

πŸ’Έ The planned sale of its minority interest in Gentiva is expected to generate about $900 million in pretax proceeds during the fourth quarter.

πŸ₯ CenterWell Primary Care added nearly 147,000 members this year, representing 30% growth including the acquisition of MaxHealth.

πŸ’Š Medical cost trends for 2026 were at the lower end of expectations, with a health technology pipeline expected to push Part D trend to 14% to 15% in 2027.

Bullish Signals
  • Humana raised its full-year 2026 adjusted earnings forecast to at least $9.50 per share from $9, driven by favorable Medicare Part D performance and medical costs at or below expectations.
  • Early Medicare Advantage enrollment trends are ahead of expectations, leading the company to anticipate membership growth in 2027.
  • Humana expects material margin improvement next year, targeting an individual Medicare Advantage margin above 3% in 2028.
  • Medicare Stars ratings significantly exceeded the top-quartile goal with a member-weighted rating of 4.17, potentially providing a one-time financial tailwind in 2028.
  • A joint venture with BlackRock reduces the company's cost of capital and is expected to lower its GAAP debt-to-capital ratio by approximately 130 basis points.
  • The sale of its minority interest in Gentiva is expected to generate about $900 million in pretax proceeds, providing significant liquidity.
  • CenterWell Primary Care added nearly 147,000 members this year, representing 30% growth and including the first-quarter acquisition of MaxHealth.
  • Medical cost trends for 2026 were at the lower end of expectations, with a health technology pipeline expected to push Part D trend to 14% to 15% in 2027.
Full Analysis
Humana Inc. (HUM) raised its full-year 2026 adjusted earnings forecast to at least $9.50 per share, up from a prior expectation of $9, driven by favorable Medicare Part D performance and medical costs that met or exceeded expectations. CEO Jim Rechtin stated the company's recovery trajectory has shifted from on plan to ahead of plan, with early Medicare Advantage enrollment trends indicating membership growth anticipated for 2027. The health insurer expects material margin improvement in 2027, targeting an individual Medicare Advantage margin above 3% by 2028. Humana's Medicare Stars ratings for the bonus year 2028 significantly exceeded its top-quartile goal with a member-weighted rating of 4.17, potentially providing a one-time financial tailwind in 2028 as the company plans to invest in Stars capabilities and customer experience. Humana announced strategic financial moves including a joint venture with BlackRock that reduces its cost of capital and lowers its GAAP debt-to-capital ratio by approximately 130 basis points. Additionally, the company expects to complete the sale of its minority interest in Gentiva during the fourth quarter, generating about $900 million in pretax proceeds, while intending to grow its dividend and increase buybacks as earnings recover.